China SXT Pharmaceuticals, Inc. (SXTC): Price and Financial Metrics
China SXT Pharmaceuticals, Inc. (SXTC)
Today's Latest Price: $0.31 USD
Updated Dec 2 4:00pm
Add SXTC to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SXTC Stock Summary
- With a year-over-year growth in debt of 1,645.91%, China SXT Pharmaceuticals Inc's debt growth rate surpasses 98.57% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, China SXT Pharmaceuticals Inc is reporting a growth rate of -532.36%; that's higher than just 3.91% of US stocks.
- As for revenue growth, note that SXTC's revenue has grown -74.91% over the past 12 months; that beats the revenue growth of just 2.21% of US companies in our set.
- Stocks that are quantitatively similar to SXTC, based on their financial statements, market capitalization, and price volatility, are BRFS, TKC, CENX, LOMA, and MT.
- SXTC's SEC filings can be seen here. And to visit China SXT Pharmaceuticals Inc's official web site, go to www.sxtchina.com.
SXTC Stock Price Chart Interactive Chart >
SXTC Price/Volume Stats
| Current price | $0.31 | 52-week high | $1.48 |
| Prev. close | $0.34 | 52-week low | $0.22 |
| Day low | $0.30 | Volume | 2,693,089 |
| Day high | $0.32 | Avg. volume | 3,353,773 |
| 50-day MA | $0.28 | Dividend yield | N/A |
| 200-day MA | $0.43 | Market Cap | 10.63M |
China SXT Pharmaceuticals, Inc. (SXTC) Company Bio
China Sxt Pharmaceuticals, Inc. engages in the development, manufacture, marketing, sales, research and development of Chinese traditional medicine. It sells Advanced TCMP, Fine TCMP and Regular TCMP products. The company sell its products under "Suxuantang" brand name. The company was founded by Zhou Feng in 2005 and is headquartered in Taizhou, China.
SXTC Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $0.31 | $0.02 | -93% |
Below please find a table outlining a discounted cash flow forecast for SXTC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that China SXT Pharmaceuticals Inc ranked in the 9th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of China SXT Pharmaceuticals Inc, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is -2.1; that's higher than only 15.88% of US stocks in the Healthcare sector that have positive free cash flow.
- The company's compound free cash flow growth rate over the past 1.87 years comes in at -0.24%; that's greater than merely 6.22% of US stocks we're applying DCF forecasting to.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -94% |
| 1% | -94% |
| 2% | -93% |
| 3% | -93% |
| 4% | -93% |
| 5% | -93% |
Want more companies with a valuation profile/forecast similar to that of China SXT Pharmaceuticals Inc? See COO, EW, LUMO, TEVA, and NVST.
Loading social stream, please wait...